ERBB2 and non-small cell lung carcinoma: Interestingly, the drug also showed activity in pretreated patients with HER2 OE NSCLC (DESTINY-Lung01 cohort 1), with ORRs around 30% and mPFS around 6 months, but did not attain an approval for this subgroup of patients [96].